Academic literature on the topic 'Pleurectomy/decortication'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pleurectomy/decortication.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pleurectomy/decortication"
Vlahu, Tedi, and Wicki T. Vigneswaran. "Pleurectomy and decortication." Annals of Translational Medicine 5, no. 11 (July 2017): 246. http://dx.doi.org/10.21037/atm.2017.04.03.
Full textHasegawa, Seiki, Masaki Hashimoto, Nobuyuki Kondo, and Yoshihiro Miyamoto. "Non-incisional pleurectomy/decortication." European Journal of Cardio-Thoracic Surgery 58, no. 1 (February 3, 2020): 186–87. http://dx.doi.org/10.1093/ejcts/ezaa012.
Full textHashimoto, Masaki, and Seiki Hasegawa. "Surgical technique of pleurectomy/decortication." Shanghai Chest 2 (2018): 44. http://dx.doi.org/10.21037/shc.2018.05.06.
Full textKaufman, Andrew J., and Raja M. Flores. "Technique of Pleurectomy and Decortication." Operative Techniques in Thoracic and Cardiovascular Surgery 15, no. 4 (2010): 294–306. http://dx.doi.org/10.1053/j.optechstcvs.2010.12.002.
Full textShah, Shagun Bhatia, Itee Chowdhury, Laleng Mawia Darlong, Priyanka Goyal, and Anamica Kansal. "Clinical Pearls in Anaesthesia for Pleurectomy/Decortication for Malignant Mesothelioma." Open Anesthesiology Journal 11, no. 1 (June 30, 2017): 29–34. http://dx.doi.org/10.2174/1874321801711010029.
Full textDi Martino, Mariano, and David A. Waller. "Pleurectomy/decortication for malignant pleural mesothelioma." Shanghai Chest 1 (2017): 13. http://dx.doi.org/10.21037/shc.2017.06.02.
Full textTakuwa, Teruhisa, and Seiki Hasegawa. "Pleurectomy/decortication for malignant pleural mesothelioma." Journal of Thoracic Disease 9, no. 3 (March 2017): 460–61. http://dx.doi.org/10.21037/jtd.2017.03.33.
Full textBilancia, Rocco, Marco Nardini, and David A. Waller. "Extended pleurectomy decortication: the current role." Translational Lung Cancer Research 7, no. 5 (October 2018): 556–61. http://dx.doi.org/10.21037/tlcr.2018.06.07.
Full textWaller, D. "IBS26.03 Surgical Technique of Pleurectomy/Decortication." Journal of Thoracic Oncology 14, no. 10 (October 2019): S119—S120. http://dx.doi.org/10.1016/j.jtho.2019.08.252.
Full textCowan, Scott W., and Taine T. Pechet. "Pleurectomy and decortication for malignant mesothelioma." Thoracic Surgery Clinics 14, no. 4 (November 2004): 517–21. http://dx.doi.org/10.1016/s1547-4127(04)00110-0.
Full textDissertations / Theses on the topic "Pleurectomy/decortication"
Bille', A. "RUOLO DELLA CHIRURGIA NEL TRATTAMENTO DEI PAZIENTI CON MESOTELIOMA PLEURICO MALIGNO:ANALISI RETROSPETTIVA E STUDIO PROSPETTICO RANDOMIZZATO SULLA CHIRURGIA DOPO CHEMIOTERAPIA VS SOLA CHEMIOTERAPIA." Doctoral thesis, Università degli Studi di Milano, 2015. http://hdl.handle.net/2434/329211.
Full textBackground Malignant pleural mesothelioma (MPM) is a rare and aggressive disease with approximately 2500 newly diagnosed cases each year in USA and about 5000 in Western Europe. Median survival is 6 to 9 months from the diagnosis, and 6-month, 1 and 5-year overall survival are 55%, 33%, and 5%, respectively. Chemotherapy alone for advanced stages, or in combination with surgery and/or radiotherapy for resectable disease, is the mainstay of treatment. Surgery with pleurectomy / decortication (P/D) or extrapleural pneumonectomy (EPP) can be an option for selected patients with resectable malignant pleural mesothelioma (MPM). Since 2003, the combination of pemetrexed and cisplatin has been the standard first-line treatment based on the results of a phase III trial showing almost a 3 month improvement in median survival over treatment with cisplatin alone. Various prognostic factors for survival in MPM have been described. Previous prognostic scoring systems for MPM included patients managed surgically and predated the use of pemetrexed. The most significant prognostic factor remains histology: epithelioid mesothelioma is the subtype with the best prognosis. The aim of this study was to investigate the impact of pleurectomy decortication on the outcome of patients with MPM. A randomized phase III multicenter controlled trial, called PASS trial was established to compare neoadjuvant chemotherapy followed by pleurectomy decortication versus chemotherapy alone. Also, a European Registry was created to collect data on surgical patients with mesothelioma not enrolled in any trials. Before enrolling patients in the PASS trial, we analyzed prognostic factors in a retrospective cohort of patients treated with chemotherapy or surgical resection and in a contemporary cohort of patients with unresectable MPM who received pemetrexed-based chemotherapy. Moreover a pilot study was conducted to evaluate the feasibility and the safety of the naodjuvant chemotherapy followed by pleurectomy/decortication. Methods We retrospectively reviewed data from 1365 consecutive patients with histologically proven MPM, treated from 1982 to 2012 in six Italian Institutions (Spedali Civili Brescia, Ospedale Maggiore della Carità Novara, San Luigi Hospital Orbassano (Torino), Policlinico hospital Milan, IRCCS San Martino Genova, Fondazione IRCCS Istituto Nazionale dei Tumori Milan). Patients received chemotherapy alone (n=172) or best supportive care (n=690) or surgical treatment (n=503), by either P/D (n=202) or EPP (n=301) with or without chemotherapy. Then a single institution analysis included MPM patients managed non-surgically from 2000-2013 at Memorial Sloan Kettering Cancer Center (MSKCC). Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial PET maximum Standardized Uptake Value (SUVmax), hemoglobin, platelet, lymphocyte, white cell (WBC) and neutrophil counts, treatment type, and clinical benefit from treatment. The pilot study included patients receiving induction pemetrexed-based chemotherapy, followed by pleuectomy decortication from September 2012 and August 2014. Postoperative morbidity and mortality and OS were analyzed. The PASS trial is a multicentric randomized trial with 2 arms. Patients were randomized at the end of the chemotherapy in 2 groups: follow up group and surgical group (pleurectomy/decortication). OS was analyzed by Kaplan-Meier method, and significance (p<0.05) of prognostic factors was analyzed by log-rank test and Cox regression. Results: After a median follow-up of 6.7 years (range 1.1-14.8), 230 (16.8%) patients were alive in the Italian retrospective study; median survival for patients who received palliative treatment or chemotherapy alone, P/D and EPP were 11.7 (95%CI: 10.5-12.5), 20.5 (95%CI: 18.2-23.1), and 18.8 (95%CI: 17.2-20.9) months, respectively. The 30 day mortality was 2.6% after P/D and 4.1% after EPP (p=0.401). According to multivariate analysis (n=1227) age < 70, epithelial histology and chemotherapy were independent favourable prognostic factors. In the subset of 313 (25.5%) patients with all favourable prognostic factors median survival was 18.6 months after medical therapy alone, 24.6 months after P/D, and 20.9 months after EPP (p=0.596). In the MSKCC contemporary series191 patients were included: median age 71 years (range 46-90), 147 (77%) male, 128 (67%) epithelioid tumors, 157 (82%) stage III-IV. Median OS for all patients was 13.4 months. By univariate analysis, histology (p<0.001), platelet count (≤450,000 vs >450,000 p<0.001), initial PS (0-1 versus ≥ 2), SUVmax (> or ≤8.1, p=0.037), and lymphocyte counts (p=0.019) were associated with OS. By multivariable analysis, only histology, platelet count and PS were independent prognostic factors. Epithelioid histology, PS and elevated lymphocyte count at diagnosis were significantly associated with clinical benefit from first-line chemotherapy. Patients who experienced clinical benefit from chemotherapy had a better median OS of 16.8 months (95% CI 14.8 – 20.1) and 1-year survival rate of 70% compared to patients who did not demonstrate clinical benefit, with a median OS of 6.5 months (95% CI 5.4 – 8.5) and 1-year survival rate of 22%. In the pilot study 16 patients were included and treated at the Fondazione IRCCS istituto Nazionale dei Tumori. All patients received neoadjuvant chemotherapy: cisplatin and pemetrexed (n=14), carboplatin and pemetrexed (n=1) or pemetrexed alone (n=1). Median number of chemotherapy cycles was 4 (range 3-8), followed by pleurectomy and decortication. Postoperative mortality was nil and the morbidity was 37%. The median OS was 22.8 months (95% CI 19.4 -26.1), with 1 and 3-year survival of 93% and 51%, respectively. During the follow up 4 paients died for mesothelioma, 12 patints were still live with a median follow up of 11 months (range 4 – 22 months). Among the 12 patients still alive, 3 were free of disease at 10, 11 and 15 months from the surgery. The remaining 9 patients recurred with a median interval of 6 months: 6 presented with a pleural local recurrence and 3 with a distant recurrence with bone metastasis (n=2) and gengival metastasis (n=1). Pass trial started in Secember 2013, until February 2015 20 patients had been evaluated and 12 were enrolled. Six patients underwent chemotherapy followed by pleurectomy decortication and 6 patients were treated with only chemotherapy and all of them are still under regular follow up. The European registry of mesothelioma, based on patients not involved in prospective studies on surgical treatment for mesothelioma, collected 3000 cases retrospectively and 11 centers so far are collecting data prospectively. Conclusions Our retrospective data from the Italian study suggest that patients with good prognostic factors had a similar survival whether they received medical therapy only, P/D or EPP. The modest benefit observed after surgery over medical treatment requires further investigation. Our results also confirm the significance of elements of the CALGB and EORTC prognostic scoring systems, identify factors associated with clinical benefit from chemotherapy, and emphasize the impact of histology and clinical benefit of chemotherapy on outcomes. A large multicenter randomized trial, testing P/D after induction chemotherapy versus chemotherapy alone in MPM patients with good prognostic factors, and a prospective European registry on surgical patients with mesothelioma are the best way to assess the real impact of the surgical treatment on survival.
Book chapters on the topic "Pleurectomy/decortication"
Flores, Raja M. "Pleurectomy and Decortication for Mesothelioma." In Chest Surgery, 403–18. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-12044-2_40.
Full textSong, Kimberly J., and Andrea S. Wolf. "Quality of Life: Extended Pleurectomy/Decortication vs Extrapleural Pneumonectomy." In Difficult Decisions in Surgery: An Evidence-Based Approach, 571–79. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-47404-1_52.
Full textCulligan, Melissa, and Joseph S. Friedberg. "Care of the Mesothelioma Patient Undergoing Extended Pleurectomy and Decortication." In Caring for Patients with Mesothelioma: Principles and Guidelines, 79–88. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-96244-3_8.
Full text"Pleurectomy and Decortication." In Specialty Imaging: Thoracic Neoplasms, 550–51. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-37706-5.50154-2.
Full textWolf, Andrea S., Assunta de Rienzo, Raphael Bueno, Lucian R. Chirieac, Joseph M. Corson, Elizabeth H. Baldini, David Jackman, et al. "Pleural mesothelioma." In Oxford Textbook of Oncology, 659–73. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199656103.003.0048.
Full textBellini, Alice, Beatrice Aramini, and Franco Stella. "Surgical Management of Malignant Pleural Mesothelioma: From the Past to the Future." In Mesothelioma - Diagnostics, Treatment and Basic Research [Working Title]. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.103686.
Full textConference papers on the topic "Pleurectomy/decortication"
Berzenji, Lawek, Dario Michaux, Suresh Krishan Yogeswaran, Annemie Van Breussegem, Patrick Lauwers, Jo Raskin, Jeroen Hendriks, Jan Van Meerbeeck, and Paul Van Schil. "Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.1718.
Full textergonul, ayse gul, ali Ozdil, tevfik ilker Akcam, kutsal Turhan, alpaslan Cakan, and Ufuk Cagirici. "Pleurectomy, decortication and hyperthermic chemotheraphy in malignant pleural mesothelioma, a single institution experience." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2458.
Full textMagouliotis, Dimitrios, Vasiliki Tasiopoulou, Kyriakos Spiliopoulos, Konstantina Svokos, Alexis Svokos, and Kalliopi Athanassiadi. "Extrapleural pneumonectomy versus pleurectomy/decortication in malignant pleural mesothelioma: an updated meta-analysis of survival endpoints." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.oa3787.
Full textMordon, Serge R., Camille Munck, Ecaterina Surmei-Pintilie, Rias Akkad, Eric Wasielewski, Gregory Baert, Pascal Deleporte, Henri Porte, and Arnaud Scherpereel. "Feasibility trial assessing intrapleural photodynamic therapy combined with pleurectomy/decortication then chemotherapy in malignant pleural mesothelioma patients." In 17th International Photodynamic Association World Congress, edited by Tayyaba Hasan. SPIE, 2019. http://dx.doi.org/10.1117/12.2526248.
Full textFalanga, F., C. Bortolotto, O. Oneta, F. Agustoni, P. Morbini, L. Saracino, S. Tomaselli, P. Rinaldi, C. Primiceri, and G. M. Stella. "Extended Pleurectomy/Decortication in Malignant Pleural Mesothelioma: preceding or following chemotherapy? Perioperative data and short-term outcomes of a single Institution." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.350.
Full textAthanassiadi, K., A. Karamolegkou, E. Tatsios, P. Zotos, K. Spiliopoulos, T. Athanasiou, and D. Magouliotis. "Comparison of survival after extrapleural pneumonectomy versus pleurectomy/decortication for malignant pleural mesothelioma in the era of macroscopic complete resection: A meta-analysis." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.1331.
Full text